^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Rectal Cancer

    Related cancers:
    1m
    Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov)
    P2, N=17, Terminated, University of Southern California | Active, not recruiting --> Terminated; Insufficient Accrual
    Trial termination
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    1m
    Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer (clinicaltrials.gov)
    P2, N=64, Recruiting, Virginia Commonwealth University | Trial completion date: Jan 2033 --> Jan 2032 | Trial primary completion date: Jan 2028 --> Jan 2030
    Trial completion date • Trial primary completion date
    |
    oxaliplatin
    1m
    Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=66, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    capecitabine • oxaliplatin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    1m
    Association of Pre-treatment CALLY Index With Pathological Response to Neoadjuvant Chemotherapy in Rectal Cancer. (PubMed, In Vivo)
    Pre-treatment inflammatory markers, including the CALLY index, may help predict pathological response to NAC in locally advanced rectal cancer.
    Journal
    |
    CRP (C-reactive protein)
    1m
    Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies (clinicaltrials.gov)
    P1/2, N=51, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD4 (CD4 Molecule)
    |
    PD-L1 negative
    |
    bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC
    1m
    BMX-001 acts as a selective chemoradioprotector in rectal cancer. (PubMed, Redox Biochem Chem)
    We also found that BMX-001 with 5-FU treatment enhanced DPYD sulfenylation, a protein known to detoxify 5-FU, and ALDH7A1 sulfenylation, a protein known to detoxify aldehydes. Together, these results suggest that BMX-001 can protect against oxidative stress in normal tissue via Nrf2 dependent and independent mechanisms.
    Journal
    |
    NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • DPYD (Dihydropyrimidine Dehydrogenase) • ALDH7A1 (Aldehyde Dehydrogenase 7 Family Member A1) • CAT (Catalase)
    |
    5-fluorouracil • BMX-001
    1m
    Longitudinal single-cell and TCR repertoire profiling characterizes clonal entrapment in patients with pMMR/MSS locally advanced rectal cancer. (PubMed, Cell Discov)
    Consequently, the immune response is limited primarily by pre-existing TCR clonotypes within the tumor, especially those partially expanded under chronic inflammation, leading to the expansion of TCR clonotypes derived mainly from pre-treatment CD8+ T cell pools following ICI therapy. By identifying this feature of the pMMR/MSS LARC microenvironment, our study provides a high-resolution framework for understanding resistance to sequential radiotherapy and ICI therapy.
    Journal • IO biomarker • pMMR
    |
    CD8 (cluster of differentiation 8) • GDF15 (Growth differentiation factor 15)
    1m
    TOPAZ: A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers (clinicaltrials.gov)
    P1, N=3, Terminated, University of Iowa | Phase classification: P1/2 --> P1 | Trial completion date: Dec 2024 --> Nov 2025
    Phase classification • Trial completion date
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    1m
    Beta-site Amyloid Precursor Protein Cleaving Enzyme 1 Overexpression Abrogates ST6GAL1 Mediated Rectal Cancer Chemoradiation Resistance. (PubMed, Cancer Genomics Proteomics)
    Collectively, we found that overexpressing BACE1 altered ST6GAL1-mediated CRT resistance in CRC cells. BACE1 enzymatic cleavage of ST6GAL1 may be a potential target for improving therapeutic response to CRT in rectal cancer.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • APP (Amyloid Beta Precursor Protein) • ST6GAL1 (ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1)
    1m
    STAR-TREC: Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? (clinicaltrials.gov)
    P2/3, N=380, Active, not recruiting, University of Birmingham | Trial primary completion date: Apr 2027 --> Aug 2027
    Trial primary completion date
    |
    capecitabine
    1m
    SPARK II: Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=76, Recruiting, Dechang Diao
    New P2 trial • pMMR
    |
    MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    Avastin (bevacizumab)
    1m
    Ill Fate of Rectal Mucinous Adenocarcinoma: A Defect in Immunosurveillance or a Mucin Coating Effect?-The IMMUNOREACT 20 Study. (PubMed, Cancers (Basel))
    The worse outcomes of rectal MAC appear to be driven largely by late-stage presentation, possibly owing to later diagnosis. MAC nonetheless carries a distinct immune phenotype, detectable even in histologically normal surrounding mucosa, that likely contributes to its treatment resistance. These observations provide a basis for developing histotype-specific approaches to both early detection and treatment in this uncommon but clinically challenging tumour subtype.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • MSH6 (MutS homolog 6) • PMS2 (PMS1 protein homolog 2) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • S100A8 (S100 Calcium Binding Protein A8) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • FOXP3 (Forkhead Box P3) • CD80 (CD80 Molecule)
    |
    nCounter® PanCancer IO 360™ Panel